AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value
Energy prices are swinging as Middle East supply risks keep traders on edge. That kind of uncertainty often pulls attention to cash flow, since it can give a clearer view of how resilient a company really is. When sentiment is jumpy, stocks with solid cash generation that still trade below estimated fair value can get overlooked. This article highlights 3 undervalued cash flow stocks from the SWS screener.
These 3 stocks are just a starting sample. The full screen surfaced 43 more companies with equally detailed cash flow stories that are not covered below.
To go straight to the source and identify ideas that fit your own risk and return preferences, analyze the Undervalued Stocks Based On Cash Flows screener.
AstraZeneca (LSE:AZN)
Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that develops and sells prescription medicines across oncology, cardiovascular and metabolic disease, respiratory and immunology, vaccines and rare diseases, working with doctors and health systems in markets from the UK and the Americas to Asia and Africa.
Operations: AstraZeneca generates about $61.4b in revenue from pharmaceuticals, reflecting a broad portfolio of branded prescription medicines.
Market Cap: £186.0b
AstraZeneca attracts attention because it combines a large oncology and rare disease pipeline with recent earnings momentum and high forecast returns on equity. It is also flagged by the cash flow screener as trading well below one estimate of fair value. Analysts cite room for further revenue and earnings growth supported by a series of recent drug approvals and positive trial updates in oncology and immunology, while the company continues to emphasise cash generation and margin improvement. The flip side is meaningful debt, heavy reliance on a handful of blockbuster drugs and ongoing pricing and regulatory pressure. For investors who want exposure to big pharma with active product news flow, that mix of strengths and risks may be worth close consideration.
AstraZeneca’s oncology pipeline and rare disease focus could be reshaping its story, yet the real twist may sit in the DCF work. See how the cash flow view stacks up in the DCF valuation analysis for AstraZeneca
Build your own cash flow and valuation shortlist
AstraZeneca and the other two stocks in this list all came from the same Simply Wall St screener, but the real value for you is in setting your own rules. Use our flexible Screener to mix filters like valuation, future growth, balance sheet strength, risks and dividends, or take a faster route by browsing our curated Investing Ideas.
Foresight Group Holdings (LSE:FSG)
Overview: Foresight Group Holdings is a London based asset manager that runs infrastructure, private equity, venture capital and listed funds for both institutions and retail investors, with a focus on renewable energy, real assets and smaller growth companies. It aims to give investors access to long term cash flows from projects such as clean energy, social infrastructure, transport and digital networks.
Operations: Foresight Group Holdings generates about £114.8 million from Real Assets and £50.1 million from Private Equity, with most revenue currently coming from the United Kingdom and Australia.
Market Cap: £552 million
Foresight Group Holdings stands out because it combines high margin infrastructure and private equity franchises with strong recent earnings momentum and share buybacks. Revenue of £164.9 million and net income of £42.8 million to March 2026 support a P/E that screens as attractive relative to peers, while analysts expect faster earnings and revenue growth than the wider UK market. At the same time, the business leans on performance fees, has higher funding risk due to reliance on external borrowing, and is heavily exposed to UK and European policy around renewables and private capital. For investors interested in cash flow rich asset managers with growth ambitions, that blend of opportunity and risk deserves closer scrutiny in the context of the screener’s undervaluation signal.
Foresight Group Holdings sits at an interesting crossroads where fee rich infrastructure cash flows and an attractive P/E are pulling ahead of sentiment. See how the full analysis report for Foresight Group Holdings hints at what could shift the story next.
BAE Systems (LSE:BA.)
Overview: BAE Systems is a London headquartered defence and aerospace company that supplies combat aircraft, warships, armoured vehicles, munitions and advanced electronics, as well as cyber security and intelligence services, to government and defence customers around the world.
Operations: BAE Systems generates about £7.8b from Electronic Systems, £7.7b from Air, £6.7b from Maritime, £5.3b from Platforms & Services and £2.4b from Cyber & Intelligence, with smaller head office activity and intra group eliminations.
Market Cap: £63.5b
BAE Systems catches the eye because it sits on a £75b order backlog tied to long term defence programmes. Analysts currently describe the stock as trading at what they see as good value relative to peers and their own cash flow estimates. Public forecasts also point to earnings and revenue growth ahead of the wider UK market, supported by higher spending commitments across NATO allies and recent contract wins in drones, space electronics and artillery systems. At the same time, heavy reliance on a handful of major government customers, ongoing ESG debates around defence and capacity bottlenecks in areas such as missiles all add real risk. For investors who want exposure to defence-related cash flows and who view current valuations as attractive, that balance of potential and risk may make BAE Systems worth a closer look.
BAE Systems’ £75b backlog and long term defence programmes suggest a story that share prices may not fully reflect. See how public expectations line up in the analyst forecasts for BAE Systems and what risk could flip that script.
Curious To Explore Smart Alternatives?
Fresh ideas can move from quiet to breakout before the crowd even glances at the charts. Consider taking action early instead of waiting while momentum develops.
- Spot resilient companies that keep compounding while others are dropping and shortlist them quickly using the list of solid balance sheet and fundamentals (21 results).
- Identify structural themes in infrastructure and electrification before they become crowded by scanning the 37 power grid technology and infrastructure stocks.
- Explore opportunities in factory automation and logistics efficiency by tracking leaders inside the 37 robotics and automation stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com